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Background—Encephalitozoon cuniculi, a microsporidial species most commonly recognized 
as a cause of renal, respiratory, and central nervous system infections in immunosuppressed 
patients, was identified as the cause of a temporally associated cluster of febrile illness among 3 
solid organ transplant recipients from a common donor.
Objective—To confirm the source of the illness, assess donor and recipient risk factors, and 
provide therapy recommendations for ill recipients.
Design—Public health investigation.
Setting—Two transplant hospitals and community interview with the deceased donor’s family.
Patients—Three transplant recipients and the organ donor.
Measurements—Specimens were tested for microsporidia by using culture, immunofluorescent 
antibody, polymerase chain reaction, immunohistochemistry, and electron microscopy. Donor 
medical records were reviewed and a questionnaire was developed to assess for microsporidial 
infection.
Results—Kidneys and lungs were procured from the deceased donor and transplanted to 3 
recipients who became ill with fever 7 to 10 weeks after the transplant. Results of urine culture, 
serologic, and polymerase chain reaction testing were positive for Encephalitozoon cuniculi of 
genotype III in each recipient; the organism was also identified in biopsy or autopsy specimens in 
all recipients. The donor had positive serologic test results for Encephalitozoon cuniculi. 
Surviving recipients received albendazole. Donor assessment did not identify factors for suspected 
Encephalitozoon cuniculi infection.
Limitation—Inability to detect organism by culture or polymerase chain reaction in donor due to 
lack of autopsy specimens.
Conclusion—Transmission of microsporidiosis through organ transplantation is described. 
Microsporidiosis is now recognized as an emerging transplant-associated disease and should be 
considered in febrile transplant recipients when tests for routinely encountered agents are 
unrevealing. Donor-derived disease is critical to assess when multiple recipients from a common 
donor are ill.
Primary Funding Source—None.
Microsporidia are spore-forming, obligately intracellular organisms related to fungi. 
Enterocytozoon bieneusi and 3 Encephalitozoon species (Encephalitozoon cuniculi, 
Encephalitozoon hellem, and Encephalitozoon intestinalis) are the most common 
microsporidia identified as pathogens of humans (1, 2). Studies indicate that asymptomatic 
microsporidial disease occurs in humans, and seroprevalence data suggest that humans may 
be frequently exposed to these organisms (3–5). Microsporidia cause a spectrum of disease, 
from self-limiting diarrhea to disseminated, life-threatening infections. Microsporidiosis is 
recognized predominantly among HIV-infected patients but has more recently been noted in 
non–HIV-infected individuals as an emerging pathogen (6, 7). Several reports describe 
microsporidial infections involving organ transplant recipients, but to our knowledge, these 
infections have not been proved to be transplant-transmitted (8–11).
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In February 2012, the Centers for Disease Control and Prevention (CDC) was notified of a 
cluster of 3 transplant recipients with febrile illness onset 7 to 10 weeks after receiving 
organs from a common donor. Initial evaluation included serologic, molecular, and culture-
based assays against a broad range of bacterial, fungal, and viral pathogens. Concomitant 
illnesses, such as urinary tract infection and organ rejection, were appropriately treated, yet 
recipients remained ill. Subsequent diagnostic evaluation of recipients suggested infections 
with a Brucella species that were presumed to be donor-derived. However, despite directed 
therapy for brucellosis and continued empirical treatment for other infectious etiologies, the 
patients did not improve, and assistance was requested from public health authorities in 
determining a common cause for the illness cluster. Kidney biopsy samples sent to CDC 
from 1 recipient confirmed the diagnosis as microsporidiosis with Encephalitozoon cuniculi, 
and a public health investigation was initiated to confirm the diagnosis in the other 
recipients, assess donor and recipient risk factors, and provide therapy recommendations for 
ill recipients.
Methods
Histopathology, Immunohistochemistry, and Electron Microscopy
Sections from formalin-fixed, paraffin-embedded tissue specimens were cut at 4 μm and 
stained using hematoxylin and eosin, Lillie-Twort and Grocott methenamine silver, and 
Warthin–Starry techniques. We examined tissues for evidence of infection with a Brucella 
or Encephalitozoon species by using an immunoalkaline phosphatase staining method. The 
primary antibodies included a monoclonal anti–Brucella abortus antibody diluted at 1/1000; 
an anti–Brucella melitensis antibody diluted at 1/200 (12); and a rabbit hyperimmune anti–
Encephalitozoon cuniculi antiserum, diluted at 1/1000, that reacts with Encephalitozoon 
cuniculi, Encephalitozoon hellem, and Encephalitozoon intestinalis (13). For examination by 
electron microscopy, formalin-fixed tissues were transferred to buffered 2.5% 
glutaraldehyde and 1% osmium tetroxide, embedded in a mixture of Epon substitute and 
Araldite, and stained with uranyl acetate and lead citrate.
Culture and Serum Testing
Encephalitozoon cuniculi was cultured in human lung fibroblast cells. Inocula consisted of 
urine sediment washed by centrifugation in Hanks balanced salt solution or renal tissue 
triturated in Modified Eagle Medium; cultures were incubated at 37.8 °C. Serum samples 
were tested for antibodies to Encephalitozoon cuniculi by an indirect immunofluorescent 
antibody (IFA) assay using spores of the organism; total antibody titers greater than 1:16 
were considered positive in the setting of immunodeficiency (14). We tested serum samples 
by using a Brucella microagglutination test with minor modifications (15). A titer of 160 or 
greater was considered positive, 20 to 80 was considered borderline, and less than 20 was 
considered negative.
Molecular Techniques
We extracted DNA from clinical samples by using a modified version of the FastDNA 
method (MP Biomedicals, Solon, Ohio), with further purification with the QIAquick 
polymerase chain reaction (PCR) purification kit (QIAGEN, Valencia, California) (16). 
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Polymerase chain reactions were performed in 50-μL total volumes by using species-specific 
diagnostic primers based on the small subunit ribosomal RNA gene of Enterocytozoon 
bieneusi, Encephalitozoon cuniculi, Encephalitozoon intestinalis, and Encephalitozoon 
hellem (17–20). We performed amplification with the diagnostic primers by using AmpliTaq 
PCR gold mix (PerkinElmer, Foster City, California); 5 μmol of each primer; and annealing 
temperatures of 55 °C for Encephalitozoon hellem PCR and 65 °C for Enterocytozoon 
bieneusi, Encephalitozoon cuniculi, and Encephalitozoon intestinalis. Genotyping of 
Encephalitozoon cuniculi was determined by analysis of the GTTT repeats in the ITS region 
(21). Brucella DNA was detected by real-time PCR using TaqMan probes targeting the 
IS711 gene (22). We considered a sample to be positive if the fluorescent growth curves 
crossed the threshold line within 45 cycles.
Epidemiologic Investigation
We reviewed medical records of the donor and organ recipients to construct a timeline of 
events and descriptions of clinical illness. A donor questionnaire was developed to assess 
potential risk factors or evidence of infection with microsporidia. The questionnaire focused 
on illnesses or exposures that would be consistent with microsporidial infection and 
included medical history, review of symptoms, recent gastrointestinal illness in the donor or 
family members, and exposures to pets or other animals.
Role of the Funding Source
This study received no funding.
Results
Organ Donor
The organ donor was a woman in her thirties who had moved to the United States from 
Mexico within the year before her death. In the autumn of 2011, she became unresponsive 
and was diagnosed with a subarachnoid hemorrhage. She progressed to brain death on the 
day of hospitalization. No illness was reported in the weeks preceding her death, and her 
medical history was unremarkable. The patient donated both kidneys and lungs, which were 
transplanted into 3 recipients; no corneas or other tissues were procured. Stored donor serum 
was tested with serologic and molecular assays, and the results showed elevated 
Encephalitozoon cuniculi titers (Table) and were negative for infection with a Brucella 
species. No autopsy was performed; however, a liver biopsy specimen obtained during 
organ procurement showed no immunohistochemical evidence of infection with a Brucella 
species or Encephalitozoon cuniculi.
Left Kidney Recipient
The recipient was a man with a history of polycystic kidney disease and hypertension who 
did well immediately after the transplant. He received induction therapy with basiliximab 
and solumedrol and maintenance therapy with tacrolimus, mycophenolic acid, and 
prednisone. He developed fever, myalgia, and fatigue approximately 9 weeks after the 
transplant (Figure 1). He was treated for urinary tract infection, neutropenia, and organ 
rejection over several hospitalizations; results of all initial tests for infectious diseases were 
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negative. His first kidney biopsy specimen showed rejection, which was treated with 
corticosteroids and thymoglobulin, and his other immunosuppressive agents were stopped. 
Because of a presumptive diagnosis of transplant-acquired brucellosis in the lung recipient, 
serum from the left kidney recipient was tested at a commercial laboratory and showed 
Brucella IgM antibodies, for which he received doxycycline and ceftriaxone. A second 
kidney biopsy specimen was obtained, and abundant intracellular organisms in renal tubular 
cells were interpreted as brucellae at a commercial laboratory by immunohistochemistry. 
The patient’s graft became tender and enlarged, and he underwent a nephrectomy 20 weeks 
after the transplant (Figure 2, A). Despite broad-spectrum antimicrobial coverage, his illness 
progressed to anuria, persistent fever, and hemodynamic instability and he died 
approximately 21 weeks after the transplant. Examination of the kidney biopsy and allograft 
nephrectomy specimen at CDC revealed histopathology consistent with microsporidiosis 
(Figure 2, B). Results of immunohistochemistry for Brucella in allograft nephrectomy 
specimens were negative. Immunohistochemistry and electron microscopy showed infection 
with an Encephalitozoon species in multiple tissues (Figure 2, C and D). Autopsy specimens 
showed disseminated infection with Encephalitozoon cuniculi (Figure 2, E and F). 
Encephalitozoon cuniculi was detected in a urine specimen by culture, IFA, and PCR and 
was identified as genotype III (Table and Figure 3). Serum was confirmed to be negative for 
Brucella by antibody and PCR testing but positive for Encephalitozoon cuniculi by antibody 
testing at CDC (Table).
Bilateral Lung Recipient
The recipient was a woman who had a bilateral lung transplant. She received induction 
therapy with basiliximab and maintenance therapy with tacrolimus, azathioprine, and 
prednisone. Seven weeks after the transplant, she developed fever, nausea, vomiting, and 
diarrhea and became encephalopathic with confusion (Figure 1). She was treated for a 
urinary tract infection and a catheter-associated bloodstream infection during her illness, but 
her fever continued. She received solumedrol for a decrease in lung function 12 weeks after 
the transplant. Secondary to continued neurologic decline and liver dysfunction, her therapy 
was changed to cyclosporine and mycophenolate mofetil at decreasing doses. Because of 
potential consumption of unpasteurized cheese from Mexico, Brucella testing was 
performed on serum and cerebrospinal fluid at a commercial laboratory and revealed IgM 
antibodies reactive with Brucella. Despite broad-spectrum coverage, including doxycycline 
and streptomycin for presumed brucellosis, she continued to have low-grade fever and 
encephalopathy and developed kidney failure. Results of pathologic evaluation of tissue 
specimens from the left kidney recipient prompted testing for microsporidia. 
Encephalitozoon cuniculi was subsequently detected in a urine specimen by culture, IFA, 
and PCR and was identified as genotype III (Table and Figure 3). It was also detected in a 
stored colon biopsy specimen collected approximately 13 weeks after the transplant. Serum 
samples were found to be positive for Brucella by microagglutination test and PCR at CDC. 
The patient also had positive serologic test results for Encephalitozoon cuniculi (Table). She 
began receiving albendazole, 400 mg twice daily, and her immunosuppression was further 
decreased; her encephalopathy and kidney function slowly improved. During month 4 of 
therapy, her medication was changed to nitazoxanide because of bone marrow suppression 
believed to be induced by albendazole. Her urine samples remained positive by PCR for 
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Encephalitozoon cuniculi until month 5 of therapy. Brucella therapy was stopped at month 6 
because of continued neutropenia. She developed a central nervous system posttransplant 
lymphoproliferative disorder and was treated with radiation and rituximab. She continued to 
receive nitazoxanide in a rehabilitation facility until her death 20 months after the transplant, 
secondary to the posttransplant lymphoproliferative disorder.
Right Kidney Recipient
The recipient was a man with diabetes and hypertension. He received induction therapy with 
basiliximab and solumedrol and maintenance therapy with tacrolimus, mycophenolic acid, 
and prednisone. Approximately 10 weeks after the transplant, he presented with fever, 
fatigue, myalgia, tremors, and joint pain. He was treated for cytomegalovirus, which was 
complicated by ganciclovir-associated thrombocytopenia and leukopenia, urinary tract 
infection, and biopsy-diagnosed organ rejection over several hospitalizations, during which 
he was treated with solumedrol; he was also noted to have BK polyomavirus viremia, for 
which his mycophenolic acid was stopped (Figure 1). Brucella testing was pursued on the 
basis of positive results in the lung recipient, but no serum IgG or IgM antibodies were 
detected. The right kidney recipient’s fatigue and weakness persisted. Urine specimens were 
evaluated after microsporidiosis was confirmed in the left kidney recipient, and infection 
with Encephalitozoon cuniculi of genotype III was confirmed by culture, IFA, and PCR 
(Table and Figure 3). A biopsy specimen of the transplanted kidney revealed 
immunohistochemical evidence of infection with Encephalitozoon cuniculi; serum was 
negative for Brucella by Brucella microagglutination test and PCR at CDC but positive for 
Encephalitozoon cuniculi by serologic testing (Table). The patient began receiving 
albendazole (400 mg orally twice daily) and gradually improved. He discontinued therapy 
after an initial 2-week course of albendazole but resumed 5 days later after presenting with 
fever, nausea, vomiting, and diarrhea; a urine specimen was positive for Encephalitozoon 
cuniculi by PCR. Results of his urine PCR were negative after 2 months of therapy. 
Albendazole was stopped 1 year after the transplant after a total of 6 months of therapy, and 
the patient remains healthy.
Epidemiologic Evaluation
Assessment with a questionnaire given to the donor’s husband did not reveal donor illnesses, 
gastrointestinal illness in other household members, or other concerning exposures 
consistent with microsporidial infection (for example, pets, wild animals, or farm animals).
Discussion
To our knowledge, we report the first recognized cluster of transplant-transmitted 
microsporidiosis linked to a common organ donor. The presence of the same 
Encephalitozoon cuniculi genotype among all 3 recipients coupled with the extremely 
elevated Encephalitozoon cuniculi titer in the organ donor confirms that this infection was 
transplant-transmitted. Increasing reports of microsporidiosis as an infectious complication 
after transplantation, now coupled with recognition of donor-derived disease, should 
heighten clinician awareness of this infection among transplant recipients. The search for a 
cause of this illness cluster, culminating in the diagnosis of microsporidiosis among these 
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organ recipients, was complicated by initial presumption of brucellosis due to positive 
Brucella test results in 2 recipients at commercial laboratories. The lung recipient was 
confirmed to be positive by serologic and PCR testing at CDC laboratories; this may 
represent a reactivation of disease or detection of a distant infection because positive results 
of Brucella PCR and antibody testing have been reported up to 2 years after infection (23, 
24). The left kidney recipient’s Brucella IgM result was not confirmed and is considered to 
be falsely positive; Brucella serologic testing requires confirmation and has been described 
as prone to yielding false-positive results (25).
Past reports of microsporidial infections primarily describe disease in HIV-infected 
individuals. Microsporidiosis has been reported in transplant recipients of solid organs, 
corneas, or bone marrow (8–11, 26, 27). However, the organ donor was not investigated as a 
potential source of infection in these reports. The symptoms of microsporidial infection vary 
on the basis of species, site of infection, and the immune status of the infected host (28). 
Enterocytozoon bieneusi is most commonly associated with persistent diarrhea, whereas 
Encephalitozoon species, including Encephalitozoon cuniculi, have been associated with 
diverse clinical syndromes, such as encephalitis, interstitial nephritis, hepatitis, 
tracheobronchitis, keratoconjunctivitis, myositis, and sinusitis (29). Asymptomatic disease 
has been reported in both immunocompetent and immunodeficient hosts (5, 30, 31). Studies 
have described latent disease among otherwise healthy individuals with intermittent spore 
shedding from stool and urine specimens; detection of microsporidial DNA in urine suggests 
that the organism is able to disseminate despite the protective effects of an intact immune 
system (5).
Seroprevalence studies have shown a frequency of 1.3% to 8% for Encephalitozoon species 
among blood donors, pregnant women, slaughterhouse workers, and dog breeders (32–34); 
seroprevalence of Enterocytozoon bieneusi was 10% among healthy blood donors but as 
high as 33% in animal keepers reporting exposure to excrement (4). These studies suggest 
that humans are frequently exposed to microsporidia and indicate that exposure to animal 
excrement could be a risk factor (4). The wide array of symptoms, the possibility of 
asymptomatic carriage, and a relatively high seroprevalence in several populations suggest 
that an unrecognized infection occurred in the organ donor; this is further supported by her 
elevated anti–Encephalitozoon cuniculi titers. Few studies have evaluated risk factors for 
microsporidial infections, but infectious sources are believed to include other infected 
humans, animals, water, and insect vectors (35). Foodborne outbreaks have also recently 
been reported (36). Exposures to microsporidia are probably common among humans given 
that the organism is ubiquitous (35, 37), but re-interview of the donor’s family did not reveal 
an obvious source of her infection or an illness potentially compatible with microsporidiosis.
Microsporidiosis should be considered in the differential diagnosis when an infectious cause 
is suspected, evaluation for common pathogens is unrevealing, and response to standard 
therapies is poor. Furthermore, transplant-transmitted disease should be considered in 
recipients when the illness is common to other patients receiving organs from the same 
donor. The diagnosis of microsporidiosis can be difficult because it requires a high index of 
suspicion, ascertainment of appropriate samples, and specialized testing. The diagnosis 
depends on identifying spores in clinical samples that are obtained on the basis of patient 
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symptoms but may include stool, urine, sputum, bronchoalveolar lavage fluid, and 
cerebrospinal fluid (28). Because the kidney is a site of disseminated infection and urine is 
easily obtainable, evaluation of urine for spores may be appropriate, especially in the 
transplant recipient (1, 11). Intermittent shedding has been described; therefore, multiple 
specimens of urine and stool collected over several months may be necessary to adequately 
evaluate patients for active infection (28). The diagnosis of microsporidiosis from urine or 
stool requires identification of spores in samples by using specialized methods that include 
Ritchie concentration, Weber trichrome stain, and fluorochrome stain, which are generally 
accessible at most medical facilities (28, 38, 39). In tissue, microsporidia stain variably with 
hematoxylin and eosin; however, Gram stain and Warthin–Starry techniques considerably 
enhance the visualization of these organisms. A species-specific identification typically 
requires electron microscopy, molecular assays, or indirect immunofluorescence or 
immunohistochemical stains that may only be available at reference laboratories. Clinicians 
can request this testing from CDC through their state and local health departments. Species-
level identification is generally needed to appropriately tailor therapy (28, 38–40). Because 
no autopsy was performed on the donor, it is unknown whether microsporidia could be 
detected in any donor tissue before transplantation; however, complete autopsies that 
include microscopic examination should be pursued routinely for organ donors, particularly 
in otherwise healthy individuals who die unexpectedly. Unexpected findings on autopsy 
specimens should be communicated immediately to the organ procurement organization 
(OPO) and public health officials. In some cases, an autopsy can identify an unsuspected or 
subclinical infection in the donor before its manifestation in recipients, thus providing the 
opportunity to initiate prophylaxis or targeted therapy to recipients.
Therapy for microsporidiosis is species-dependent, and finding a tolerable option can be 
challenging in a transplant recipient. Encephalitozoon species, including Encephalitozoon 
cuniculi, are treatable with albendazole, but this agent is not effective against 
Enterocytozoon bieneusi (28, 40, 41). For severely ill patients, which transplant recipients 
often are, oral medications may be unsuitable because of poor gastrointestinal function. In 
such cases, physicians may consider Fumagillin, which is efficacious against 
Encephalitozoon species and Enterocytozoon bieneusi (28, 40, 41). Fumagillin is not 
approved for use in humans in the United States but is available commercially for veterinary 
purposes; however, a compassionate use application would need to be filed through the U.S. 
Food and Drug Administration. Alternatively, centers can request an emergency 
investigational new drug application from the U.S. Food and Drug Administration to obtain 
the drug from the manufacturer. The adverse effects associated with both drugs, including 
gastrointestinal upset and variable degrees of bone marrow suppression, further complicate 
management of the condition.
The appropriate duration of therapy required to eradicate infection with Encephalitozoon 
cuniculi in transplant recipients is unknown. There have been reports of relapse as long as 1 
year after cessation of therapy and positive urine PCR results after more than 5 months of 
therapy. In this cluster, we chose to monitor the recipients by using PCR testing on urine 
specimens. The surviving kidney recipient had no detectable organisms in urine specimens 
within 2 months of starting therapy, whereas the lung recipient remained positive until 
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completing 5 months of therapy. Variable degrees of immunosuppression among transplant 
recipients may also be considered as a reason for differences in response; immune 
reconstitution in HIV-positive individuals has proved to be an effective treatment method 
but may not be feasible in transplant recipients (39).
The frequency of transplant-transmitted microsporidiosis is unknown. Investigation of 
microsporidia transmission from the donor in previously reported transplant patients with 
microsporidiosis may not have been done, especially if other recipients from a common 
donor were not known to be ill. Recognition of donor-derived illness clusters can only occur 
when notification is given to the OPO and public health authorities. Organ Procurement and 
Transplantation Network (OPTN) policy requires reporting of potential donor-derived 
disease by both OPOs and transplant centers. Transplant centers should notify the OPO of 
any illness in a recipient believed to be transplant-transmitted so that an assessment of the 
health status of other recipients can take place; the OPO and transplant center should also 
notify OPTN as required. Should it be discovered that other organ recipients are ill or if the 
pathogen is a nationally notifiable disease, public health authorities should be notified to aid 
in the investigation. Any illness of unknown cause or poorly responsive disease found to be 
present in multiple organ recipients should be immediately reported to the OPO, OPTN, and 
public health authorities upon discovery by treating physicians. This process is particularly 
crucial in circumstances such as the cluster described in this report, when an unusual, 
unsuspected, or previously unknown transplant-associated pathogen is involved. Rapid 
diagnosis and appropriate therapy may improve outcomes in recipients with transplant-
transmitted pathogens and may also reduce the risk for further transmission.
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Services, Austin, Texas; Mam Ibraheem MD, MPH, CPH, New Mexico Department of 
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Microsporidia, such as Encephalitozoon cuniculi, are ubiquitous organisms related to 
fungi and may be acquired by animal contact. They can cause protean systemic disease 
that is especially severe in immunocompromised hosts.
Contribution
Investigation of a temporal cluster of severe febrile illness in 3 solid organ transplant 
recipients revealed infection with Encephalitozoon cuniculi of genotype III. Two patients 
died. The donor had serologic evidence of infection with the same organism.
Caution
Donor tissue was not available for additional testing. No risk factors for acquisition were 
found.
Implication
Microsporidiosis should be considered in febrile transplant patients when commonly 
encountered infections are not found or when response to standard therapies is poor, and, 
donor-derived disease should be considered when multiple recipients who received 
organs from the same donor are ill.
—The Editors
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Timeline of Events for Recipients
Initial posttransplant recovery was unremarkable for all recipients until fever onset 7 to 10 
weeks after transplant. BK = BK polyomavirus viremia; BSI = bloodstream infection; CMV 
= cytomegalovirus infection; UTI = urinary tract infection.
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Gross and microscopic pathology of tissues from the left kidney recipient.
A: Explanted kidney showing multiple microabscesses and hemorrhages of the renal 
capsule. B: Intracellular masses of Encephalitozoon cuniculi within renal tubular epithelium 
in the explanted kidney (original magnification × 100). C: Immunohistochemical staining of 
Encephalitozoon cuniculi (red) in the explanted kidney (original magnification × 25). D: 
Electron micrograph of a spore of Encephalitozoon cuniculi, surrounded by a dense 
exospore and electron-lucent endospore and containing 5 cross-sections through the coils of 
the polar filament, as is typical for this microsporidian (bar, 100 nm). E and F: Evidence of 
disseminated microsporidiosis involving thyroid gland (E) and liver (F) (original 
magnification × 100). Encephalitozoon cuniculi organisms were detected in several other 
tissues, including the central nervous system, heart, trachea, lung, pancreas, adrenal gland, 
gallbladder, prostate gland, stomach, colon, and vascular smooth muscle.
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Encephalitozoon cuniculi immunofluorescent antibody in kidney section.
The spores were birefringent and variably Gram-positive. Stained smears of all initial urine 
specimens from all recipients revealed oval spores characteristic of microsporidia. The 
spores fluoresced brightly when reacted with a 1:400 dilution of the rabbit antiserum made 
against Encephalitozoon cuniculi.
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Table
Laboratory Testing of Clinical Samples for Encephalitozoon cuniculi
Patient Serum Titer* (Total Antibody) Urine Culture Result Urine PCR Result Genotype
Lung recipient 1:128 to 1:256 Positive Positive III
Right kidney recipient 1:32 to 1:128 Positive Positive III
Left kidney recipient 1:64 Positive Positive III
Organ donor† 1:4096 NA NA NA




Stored splenocytes and lymphocytes were tested with PCR, but Encephalitozoon cuniculi was not detected
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